---
title: "Denali Therapeutics to sell rare pediatric disease priority review voucher for $195 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290194742.md"
description: "Denali Therapeutics agreed to sell a Rare Pediatric Disease Priority Review Voucher for $195 million. The voucher was awarded following the FDA's accelerated approval of AVLAYAH for Hunter syndrome in March 2026. Proceeds will fund the development of Denali’s TransportVehicle-enabled pipeline for lysosomal storage disorders and neurodegenerative diseases. Closing is subject to customary conditions, including the expiration of the Hart-Scott Rodino waiting period."
datetime: "2026-06-18T12:05:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290194742.md)
  - [en](https://longbridge.com/en/news/290194742.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290194742.md)
---

# Denali Therapeutics to sell rare pediatric disease priority review voucher for $195 million

-   Denali Therapeutics agreed to sell a Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 195 million. \* The voucher was awarded following FDA accelerated approval of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome in March 2026. \* Proceeds are slated to fund development of Denali’s TransportVehicle-enabled pipeline in lysosomal storage disorders and neurodegenerative diseases. \* Closing remains subject to customary conditions, including expiration of the Hart-Scott Rodino waiting period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001714899-26-000081), on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [DNLI.US](https://longbridge.com/en/quote/DNLI.US.md)

## Related News & Research

- [Groupama Asset Managment Grows Stock Position in Denali Therapeutics Inc. $DNLI](https://longbridge.com/en/news/294581286.md)
- [Denali wins FDA accelerated approval for Hunter syndrome brain-penetrant enzyme therapy AVLAYAH](https://longbridge.com/en/news/292237326.md)
- [Kazia Therapeutics Files Provisional Patent Backing New Paxalisib Strategy in High-Risk Early TNBC](https://longbridge.com/en/news/294061781.md)
- [Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall?](https://longbridge.com/en/news/294229928.md)
- [Kazia Therapeutics files provisional patent for strategy to prevent metastatic recurrence in triple-negative breast cancer](https://longbridge.com/en/news/294058325.md)